🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Shout-out to these rising stars in #cancerresearch! You represent the future of the field, and we are thrilled that you are sharing your talents with the Memorial Sloan Kettering Cancer Center community.

Clinical Trials Plenary Session: Advances in Immunotherapy — Researchers presented impactful clinical trial results on Sunday at #AACR25. Read a recap in AACR Annual Meeting News: aacrmeetingnews.org/news/first-cli…

We're wrapping up #AACR25 on a strong note! Swing by the Exhibit Hall from now until 12pm CT to learn from our MSK experts and their work in clinical research and #cancer prevention. AACR

This past weekend, Memorial Sloan Kettering Cancer Center welcomed a global audience to the 9th Annual Symposium on #Lymphoma, held both in New York City and virtually. We extend our sincere appreciation to all the presenters for their valuable insights—including keynote speakers Christopher Flowers,

🫁 Zoldonrasib showed “encouraging initial antitumor activity” in patients with NSCLC who are harboring the #KRAS G12D mutation, according to a study presented at #AACR25 by Kathryn C. Arbour of Memorial Sloan Kettering Cancer Center. ➡️ Learn more: lungcancerstoday.com/post/zoldonras… #lcsm #NSCLC AACR

Although we will miss her Memorial Sloan Kettering Cancer Center and in our GMO group, there are only congratulations for Claire Friedman MD as she embarks on the next phase of her career! MSKCC Team Uterus Team Ovary, Memorial Sloan Kettering Cancer Center MSK Department of Medicine

🌟 Jaw-Dropper at AACR 2025! 🚀 Dr. Cercek unveils PD-1 immunotherapy results for MMRd/MSI-H tumors 🔸92% RFS at 2 years for 117 patients 🔸35% with no side effects 🔸Surgery avoided for many! See our companion video overview! 🔸🩺🎬👇 ARTICLE: oncologytube.com/pd-1-immunothe…

After the U.S. FDA expanded the indication for lutetium Lu 177 vipivotide tetraxetan, Michael J. Morris, MD, discussed: ⭐️ The design and enrollment criteria for PSMAfore. ⭐️ Key efficacy data that supported the approval. ⭐️ The importance of QOL outcomes hubs.li/Q03kXxlD0

Grateful to ESMO - Eur. Oncology for the opportunity to share and promote our latest work. In this recent paper (👉 lnkd.in/dNVQbtMD), we present a comprehensive overview of the current applications of AI applied to cancer pathology and explore how this field is rapidly evolving

DB-11 press release today, increased pCR with TDXD followed by THP as neoadjuvant Rx for HER2+ early breast cancer right on the heels of DB-09 that showed improved benefit with TDXD plus P vs THP for met disease-to be presented at ASCO buff.ly/2P1Q0h6

Congrats to Mark G. Kris, Kenneth Offit, David G. Pfister, and Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 on being inducted into the 13th Giants of Cancer Care® class by OncLive.com! This award honors leading physicians who are advancing #cancerresearch. Memorial Sloan Kettering Cancer Center Learn more: bit.ly/42Ox58M

Happy to share our editorial and thoughts about the AQUILA trial recently published in NEJM. Thanks Leif Bergsagel for involving me in this effort! 🙏 #msmm Memorial Sloan Kettering Cancer Center MSK Department of Medicine Mayo Clinic nejm.org/doi/full/10.10…

Watch James J. Harding, MD, of Memorial Sloan Kettering Cancer Center discuss efficacy data with nivolumab plus ipilimumab that led to this regimen’s FDA approval for unresectable or metastatic hepatocellular carcinoma. Watch the full video here: hubs.li/Q03lpcvc0

MSK is pleased to announce TIME has named two MSK physician-scientists, Andrea Cercek and Vinod BalachandranMD, to the 2025 TIME100 Health, a list of the 100 most influential individuals in health and medicine who have made significant contributions to improving global health outcomes,

Memorial Sloan Kettering Cancer Center MSK Department of Medicine

.Isabel Preeshagul of Memorial Sloan Kettering Cancer Center discusses frontline treatment selection for patients with SCLC and expanded on the significance of several regulatory milestones for this disease. #lcsm #oncology onclive.com/view/tarlatama…

🚨The FDA granted accelerated approval to avutometinib & defactinib for adults with KRAS-mutated recurrent low-grade serous #ovariancancer. Congrats to MSK's Rachel Grisham, Global Lead Principal Investigator of GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301! bit.ly/3ETZS2F

Excited to share our work investigating the mutagenic impact of radiotherapy in hematological cancers out today in Blood Cancer Discovery!! 🎉 Another study born from amazing collaborations across Moffitt Cancer Center Heidelberg Myeloma University of Miami Memorial Sloan Kettering Cancer Center MSK Department of Medicine 💪 #lysm #wgs #RT #mmsm

Congratulations Ghassan Abou-Alfa!